Skip to text Skip to main menu

SCIENCE & TECHNOLOGY

ABBIO’S CORE TECHNOLOGIES : (ADVANCED) sCAR-T TECH

Conventional CAR-T therapy

Context for CAR-T therapy

The evolution of anticancer drugs has progressed from cytotoxic chemotherapy agents to targeted therapies such as mAbs, and more recently, to adoptive cell therapies. Unlike cytotoxic agents, which lack specificity, or targeted therapies that rely on the patient’s immune system, adoptive cell therapies (CAR-T) offer a more autonomous approach to eradicating cancer cells while maintaining precise target specificity.

Efficacy of CAR-T treatment against blood cancers

  • ORR: overall response rate
  • CR: complete remission
CAR-T therapy shows significant therapeutic effects
compared to previous treatments

Limitations of conventional CAR-T treatment

Blood cancer

Relapse rate
≥40%

CRS (Grade 3-5)
~20%

ICANS (Grade 3-4)
~35%

Solid tumor

Difficult to treat

CRS, Cytokine Release Syndrome; ICANS, Immune effector Cell-Associated Neurotoxicity Syndrome

However, current CAR-T
therapy needs to be
improved to overcome
several limitations

Causal agents evoking the limitations of
conventional CAR-T therapy

Tumor side

Blood cancer

Antigen downregulation

Immunosuppressive TME

Solid cancer

Antigen heterogeneity

Immunosuppressive TME

Low accessibility

T cell side

On-target, off-tumor toxicity

Excessive secretion of cytokines

T cell exhaustion (expression of inhibitory receptor)